

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
00-1206-BSerial No.
09/993,245INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Applicant: Alex Burgin, et al.

Filing Date: 11/14/01

Group: 1623
1652

TECH CENTER 1600/2900

OCT 25 2002

RECEIVED

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date
DS	1.	6,039,804	03/21/00	Kim, et al.	117	206	09/9/98

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes No

OTHER DOCUMENTS - Including Author, Title, Date, Pertinent Pages, Etc.

DS	2.	Berger, J., "Structure of DNA Topoisomerases," <i>Biochimica et Biophysica Acta</i> 1400 p. 3-18 (1998)
DS	3.	Giegè, R., et al., "Crystallogensis of Biological Macromolecules. Biological, Microgravity and Other Physicochemical Aspects," <i>Prog. Crystal Growth and Charact</i> , Volume 30, p. 237-281 (1995)
DS	4.	Pommier, Y., et al., "Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme," <i>Biochimica et Biophysica Acta</i> 1400, p. 83-106 (1998)
DS	5.	Redinbo, M., et al., "Novel Insights into Catalytic Mechanism from a Crystal Structure of Human Topoisomerase I in Complex with DNA," <i>Biochemistry</i> , Volume 39, p. 6832-6840 (2000)
DS	6.	Redinbo, M., et al., "Structural Flexibility in Human Topoisomerase I Revealed in Multiple Non-isomorphous Crystal Structures," <i>J. Mol. Biol.</i> Volume 292, p. 685-696 (1999)
DS	7.	Redinbo, M., et al., "Crystal Structures of Human Topoisomerase I Covalent and Noncovalent Complexes with DNA," <i>Science</i> , Volume 279, p. 1504-1513 (1998)
DS	8.	Stewart, L., et al., "A Model for the Mechanism of Human topoisomerase I," <i>Science</i> , Volume 279, p. 1534-1541 (1998)

Examiner

Date Considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with any communication.

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 00-1206-B	Serial No. 09/993,245	RECEIVED NOV 19 2002 TECH CENTER 1500/2900
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: Alex Burgin, et al.		
		Filing Date: 11/14/01	Group: 1623 1652	

U.S. PATENT DOCUMENTS


Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date
DJS	1.	5,004,758	04/02/91	Boehm, et al.	514	283	11/02/88
DJS	2.	5,070,192	12/03/91	Earnshaw, et al.	536	27	03/23/88
DJS	3.	5,856,116	01/05/99	Wilson, et al.	435	23	05/25/95

FOREIGN PATENT DOCUMENTS


		Document Number	Date	Country	Class	Subclass	Translation Yes No
DJS	4.	WO 99/45379 -	09/10/99	PCT			
DJS	5.	WO 00/14105 -	03/16/00	PCT			

OTHER DOCUMENTS - Including Author, Title, Date, Pertinent Pages, Etc.

DJS	6.	Burgin Jr., A. B., et al., "A novel suicide substrate for DNA topoisomerases and site-specific recombinases," <i>Nucleic Acids Res.</i> , Volume 23, pp. 2973-2979 (1995).
DJS	7.	Champoux, J. J., "DNA Topoisomerases: structure, function, and mechanism," <i>Ann. Rev. Biochem.</i> , Volume 70, pp. 369-413 (2001).
DJS	8.	Chen, A. Y., et al., "DNA topoisomerases: Essential enzymes and lethal targets," <i>Rev. Pharmacol. Toxicol.</i> , Volume 34, pp. 191-218 (1994).
DJS	9.	Chourpa, I., et al., "Modulation in kinetics of lactone ring hydrolysis of camptothecins upon interaction with topoisomerase I cleavage sites on DNA," <i>Biochem.</i> , Volume 37, pp. 7284-7291 (1998).
DJS	10.	Cushman, M., et al., "Synthesis of new indeno[1,2-c]isoquinolines: cytotoxic non-camptothecin topoisomerase I inhibitors," <i>J Med Chem</i> , Volume 5, pp. 3688-3698 (2000).
DJS	11.	D'Arpa P., et al., "cDNA cloning of human DNA topoisomerase I: catalytic activity of a 67.7-kDa carboxyl-terminal fragment," <i>Proc Natl. Acad. Sci USA</i> , Volume 85, p. 2543-2547 (1988).
DJS	12.	Fertala, J., et al., "Substitutions of Asn-726 in the active site of yeast DNA topoisomerase I define novel mechanisms of stabilizing the covalent enzyme-DNA intermediate," <i>J. Biol. Chem</i> , Volume 275, pp. 15246-15253 (2000).

Examiner 	Date Considered 09-01-04
---	-----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with any communication.

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 00-1206-B	Serial No. 09/993,245
INFORMATION DISCLOSURE STATEMENT BY APPLICANT 		Applicant: Alex Burgin, et al.	
		Filing Date: 11/14/01	Group: 1623 <i>165</i>

U.S. PATENT DOCUMENTS


Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation Yes No


OTHER DOCUMENTS - Including Author, Title, Date, Pertinent Pages, Etc.

<i>DS</i>	13.	Fiorani, P., et al., "Domain interactions affecting human DNA topoisomerase I catalysis and camptothecin sensitivity," <i>Mol Pharmacol</i> , Volume 56, pp. 1105-1115 (1999). —
<i>DS</i>	14.	Giovannella, B. C., et al., "DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts," <i>Science</i> , Volume 246, pp. 1046-8 (1989). —
<i>DS</i>	15.	Hertzberg, R. P., et al., "On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex," <i>Biochem.</i> , Volume 28, pp. 4629-4638 (1989). —
<i>DS</i>	16.	Hsiang, Y. H., et al., "Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I," <i>J. Biol. Chem.</i> , Volume 260, pp. 14873-14878 (1985). —
<i>DS</i>	17.	Hsiang, Y. H., et al., "DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues," <i>Cancer Res</i> , Volume 49, pp. 4385-9 (1989). —
<i>DS</i>	18.	Kehrer, D. F. S., et al., "Modulation of camptothecin analogs in the treatment of cancer: a review," <i>Anti-Cancer Drugs</i> , Volume 12, pp. 89-105 (2001). —
<i>DS</i>	19.	Krogh, B. O., et al., "Catalytic mechanism of DNA topoisomerase IB," <i>Mol. Cell</i> , Volume 5, pp. 1034-1041 (2000). —

Examiner 	Date Considered <i>09-01-04</i>
---	------------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with any communication.

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 00-1206-B	Serial No. 09/993,245	RECEIVED NOV 19 2002 TECH CENTER 1600/2900
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: Alex Burgin, et al.		
		Filing Date: 11/14/01	Group: 1623 1652	



U.S. PATENT DOCUMENTS


Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation Yes No

OTHER DOCUMENTS - Including Author, Title, Date, Pertinent Pages, Etc.

DS	20.	Li, X. G., et al., "Involvement of amino acids 361 to 364 of human topoisomerase I in camptothecin resistance and enzyme catalysis," <i>Biochem. Pharmacol.</i> , Volume 53, pp. 1019-1027 (1997).
DS	21.	Nitiss, J. L. and Wang, J. C., "DNA topoisomerase-targeting antitumor drugs can be studied in yeast," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , Volume 85, pp. 7501-7505 (1988).
DS	22.	Redinbo, M. R., et al., "Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA," <i>Science</i> , Volume 279, pp. 1504-1513 (1998).
DS	23.	Rubin, E., et al., "Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitro-camptothecin," <i>J Biol Chem</i> , Volume 269, pp. 2433-2439 (1994).
DS	24.	Stewart, L., et al., "A functional linker in human topoisomerase I is required for maximum sensitivity to camptothecin in a DNA relaxation assay," <i>J. Biol. Chem.</i> , Volume 274, pp. 32950-32960 (1999).

Examiner 	Date Considered 09-01-04
---	-----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with any communication.

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
00-1206-BSerial No.
09/993,245INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Applicant: Alex Burgin, et al.

Filing Date: 11/14/01

Group: 1623
1652

TECH CENTER 1600/2800

NOV 18 2002

RECEIVED

US. PATENT DOCUMENTS


Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation Yes No


OTHER DOCUMENTS - Including Author, Title, Date, Pertinent Pages, Etc.

DS	25.	Stewart, L., et al., "A model for the mechanism of human topoisomerase I," <i>Science</i> , Volume 729, pp. 1534-1541 (1998). -
DS	26.	Stewart, L., et al., "Biochemical and biophysical analyses of recombinant forms of human topoisomerase I," <i>J. Biol. Chem.</i> , Volume 271, pp. 7593-7601 (1996). -
DS	27.	Stewart, L., et al., "Reconstitution of human topoisomerase I by fragment complementation," <i>J. Mol. Biol.</i> , Volume 269, pp. 355-372 (1997).
DS	28.	Strumberg, D., et al., "Synthesis of cytotoxic indenoisoquinoline topoisomerase I poisons," <i>J Med Chem</i> , Volume 11, pp. 446-457 (1999).
DS	29.	Smith, J. L., Hendrickson, W. A., Honzatko, R. B., Sheriff, S., "Structural heterogeneity in protein crystals," <i>Biochem.</i> , Volume 25, pp. 5018-5027 (1986).
DS	30.	Tamura, H., et al., "Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites," <i>Nucleic Acids Res.</i> , Volume 19, pp. 69-75 (1991).

Examiner 	Date Considered 09-01-04
---	-----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with any communication.

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
00-1206-BSerial No.
09/993,245INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

RECEIVED

Applicant: Alex Burgin, et al.

DEC 03 2002

Filing Date: 11/14/01

Group: 1623

TECH CENTER 1600/2900

1652

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation Yes No

OTHER DOCUMENTS - Including Author, Title, Date, Pertinent Pages, Etc.

DIS	1.	Brünger, A. T., et al., "Crystallography and NMR system: A new software system for macromolecular structure determination," <i>Acta. Crystallographica</i> , D54, pp. 905-921 (1998)
DIS	2.	Champoux, J. J., "Structure-based analysis of the effects of camptothecin on activities of human topoisomerase I," <i>Ann. N. Y. Acad. Sci.</i> , Volume 922, pp. 56-64 (2000).
DIS	3.	McRee, D.E., "XtalView/Xfit- A Versatile Program for Manipulating Atomic Coordinates and Electron Density," <i>J. Struct. Bio.</i> , Volume 125, p. 156-165 (1999)
DIS	4.	Navaza, J., "AMORE: an automated package for molecular replacement," <i>Acta. Crystallogr.</i> , A50, pp. 157-163 (1994).
DIS	5.	Otwinoski, Z., et al., "Processing of X-ray diffraction data in oscillation mode," <i>Methods. Enzymol.</i> , Volume 276, pp. 307-326 (1997).
DIS	6.	Rodgers, D. W., "Cryocrystallography," <i>Structure</i> , Volume 2, pp. 1135-1140 (1994).
DIS	7.	Sheldrick, G., et al., "SHELXL: High-resolution Refinement," <i>Methods in Enzymology</i> , Volume 277, pp. 319-343 (1997).
DIS	8.	Wall, M. E., et al., "The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from <i>Camptotheca acuminata</i> ," <i>J. Am. Chem. Soc.</i> , Volume 88, pp. 3888-3890 (1966)

Examiner

Date Considered

09-01-04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with any communication.